Vantage logo

Esketamine floats past adcom vote

Johnson & Johnson's esketamine should get approved in depression, but a safety plan requiring supervision raises questions about its commercial promise.

Vantage logo

Daybreak clouds over for Lundbeck

A treatment-resistant schizophrenia drug would have been a blockbuster – but Lundbeck’s high risk, high-reward strategy has not paid off.